LIPOXIN A4 Property

Boiling point:

589.4±50.0 °C(Predicted)

Density 

1.096±0.06 g/cm3(Predicted)

storage temp. 

-20°C

solubility 

A solution in ethanol, can isomerize and degrade when put into freeze thaw conditions or in solvents such as DMSO, or DMF, 50 mg/ml in Ethanol, 1 mg/ml in PBS (pH 7.2)

form 

ethanol solution

pka

4.67±0.10(Predicted)

color 

Colorless to light yellow

Safety

Hazard Codes 

F

Risk Statements 

11

Safety Statements 

7-16

RIDADR 

UN 1170 3/PG 2

WGK Germany 

1

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Danger

Hazard statements

H225Highly Flammable liquid and vapour

H319Causes serious eye irritation

Precautionary statements

P210Keep away from heat/sparks/open flames/hot surfaces. — No smoking.

P233Keep container tightly closed.

P240Ground/bond container and receiving equipment.

P241Use explosion-proof electrical/ventilating/lighting/…/equipment.

P242Use only non-sparking tools.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

LIPOXIN A4 Chemical Properties,Usage,Production

Description

Lipoxin A₄ (LXA₄) is a trihydroxy fatty acid containing a conjugated tetraene, produced by the metabolism of 15-HETE or 15-HpETE with human leukocytes. LXA₄ is equipotent to leukotriene B₄ (LTB₄; Item Nos. 10007240 | 20110) in inducing superoxide generation in human neutrophils at 0.1 μM. LXA₄ is associated with several other biological functions including leukocyte activation, chemotaxis effects, natural killer cell inhibition, and monocyte migration and adhesion.

LXA₄ MaxSpec^® standard is a quantitative grade standard of LXA₄ that has been prepared specifically for mass spectrometry and related applications where quantitative reproducibility is required. The solution has been prepared gravimetrically and is supplied in a deactivated glass ampule sealed under argon. The concentration was verified by comparison to an independently prepared calibration standard. This LXA₄ MaxSpec^® standard is guaranteed to meet identity, purity, stability, and concentration specifications and is provided with a batch-specific certificate of analysis. Ongoing stability testing is performed to ensure the concentration remains accurate throughout the shelf life of the product. Note: The amount of solution added to the vial is in excess of the listed amount. Therefore, it is necessary to accurately measure volumes for preparation of calibration standards. Follow recommended storage and handling conditions to maintain product quality.

Uses

Lipoxin A4 (LXA4) is a trihydroxy fatty acid containing a conjugated tetraene, produced by the metabolism of (±)15-HETE or 15-HpETE with human leukocytes. LXA4 is equipotent to leukotriene B4 in inducing superoxide generation in human neutrophils at 0.1 μM. LXA4 is associated with several other biological functions including leukocyte activation, chemotaxis effects, natural killer cell inhibition, and monocyte migration and adhesion. Analytical and biological comparisons of synthetic LXA4 with endogenously derived LXA4 have confirmed its identity as matching the natural product.

Uses

Lipoxin A4 is a trihydroxy fatty acid produced through 15-HETE metabolism.

Definition

ChEBI: A C20 hydroxy fatty acid having (5S)-, (6R)- and (15S)-hydroxy groups as well as (7E)- (9E)-, (11Z)- and (13E)-doubl bonds.

General Description

Caution! Product contains volatile liquid. Keep product cold at all times.

Biochem/physiol Actions

Lipoxin A4 (LXA4) is synthesized from arachidonic acid and is an endogenous lipoxygenase-derived eicosanoid mediator. It is a potent human protein kinase C activator. It inhibits cytotoxicity of natural killer cells. LXA4 regulates the immune system and inflammation. In the brain, it modulates neuronal signaling and slow wave sleep. LXA4 binds to cannabinoid receptors. LXA4 plays a key role in the maintenance of endometrium and reproductive function. Depletion of LXA4 contributes to the pathophysiology of cystic fibrosis (CF).